Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Amoxicillin concentrations in relation to beta-lactamase activity in sputum during exacerbations of chronic obstructive pulmonary disease

Authors Brusse-Keizer M, VanderValk P, van der Zanden R, Nijdam L, van der Palen J, Hendrix R, Movig K

Received 1 July 2014

Accepted for publication 5 September 2014

Published 3 March 2015 Volume 2015:10(1) Pages 455—461

DOI https://doi.org/10.2147/COPD.S70355

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Marjolein Brusse-Keizer,1 Paul VanderValk,2 Rogier W van der Zanden,3 Lars Nijdam,4 Job van der Palen,1,5 Ron Hendrix,6,7 Kris Movig4

1Medical School Twente, 2Department of Pulmonary Medicine, Medisch Spectrum Twente, Enschede, 3Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, 4Department of Clinical Pharmacy, Medisch Spectrum Twente, 5Department of Research Methodology, Measurement and Data Analysis, University of Twente, 6Regional Laboratory of Public Health, Enschede, 7Department of Medical Microbiology, University Medical Centre Groningen, and University of Groningen, Groningen, the Netherlands
 
Background: Acute exacerbations of chronic obstructive pulmonary disease (COPD) are often treated with antibiotics. Theoretically, to be maximally effective, the antibiotic concentration at sites of infection should exceed the minimum inhibitory concentration at which 90% of the growth of potential pathogens is inhibited (MIC90). A previous study showed that most hospitalized COPD patients had sputum amoxicillin concentrations <MIC90 when treated with amoxicillin/clavulanic acid. Those with adequate sputum concentrations had better clinical outcomes. Low amoxicillin concentrations can be caused by beta-lactamase activity in the lungs. This study investigated whether patients with sputum amoxicillin concentrations <MIC90 had higher beta-lactamase activity in sputum than patients with a concentration ≥MIC90.
Methods: In total, 23 patients hospitalized for acute exacerbations of COPD and treated with amoxicillin/clavulanic acid were included. Sputum and serum samples were collected at day 3 of treatment to determine beta-lactamase activity in sputum and amoxicillin concentrations in both sputum and serum.
Results: We found no difference in beta-lactamase activity between patients with sputum amoxicillin concentrations <MIC90 and ≥MIC90 (P=0.79). Multivariate logistic regression analysis showed no significant relationship between beta-lactamase activity and sputum amoxicillin concentrations <MIC90 or ≥MIC90 (odds ratio 0.53; 95% confidence interval 0.23–1.2; P=0.13). Amoxicillin concentrations were <MIC90 in 78% of sputum samples and in 30% of serum samples.
Conclusion: In patients treated with amoxicillin/clavulanic acid for an acute exacerbation of COPD, sputum beta-lactamase activity did not differ between those with sputum amoxicillin concentrations <MIC90 or ≥MIC90. The finding that the majority of patients had sputum amoxicillin concentrations <MIC90 suggests that current treatment with antibiotics for acute exacerbations of COPD should be optimized.

Keywords: chronic obstructive pulmonary disease, exacerbation, amoxicillin, clavulanic acid, MIC90, concentration
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Antimicrobial activity of cream incorporated with silver nanoparticles biosynthesized from Withania somnifera

Marslin G, Selvakesavan RK, Franklin G, Sarmento B, Dias ACP

International Journal of Nanomedicine 2015, 10:5955-5963

Published Date: 22 September 2015

C-reactive protein levels in stable COPD patients: a case-control study

Silva DR, Gazzana MB, Knorst MM

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1719-1725

Published Date: 31 August 2015

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease

Nishijima Y, Minami S, Yamamoto S, Ogata Y, Koba T, Futami S, Komuta K

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:439-444

Published Date: 27 February 2015

Antibiotics against Pseudomonas aeruginosa for COPD exacerbation in ICU: a 10-year retrospective study

Planquette B, Péron J, Dubuisson E, Roujansky A, Laurent V, Le Monnier A, Legriel S, Ferre A, Bruneel F, Chiles PG, Bedos JP

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:379-388

Published Date: 17 February 2015

Associated bone mineral density and obstructive sleep apnea in chronic obstructive pulmonary disease

Wang TY, Lo YL, Chou PC, Chung FT, Lin SM, Lin TY, Lin HC, Wang CH, Yu CT, Kuo HP

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:231-237

Published Date: 29 January 2015

Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease

Brockwell C, Ampikaipakan S, Sexton DW, Price D, Freeman D, Thomas M, Ali M, Wilson AM

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:715-721

Published Date: 9 July 2014